Side-by-side comparison of AI visibility scores, market position, and capabilities
London UK commercial motor insurtech ($1.1B unicorn 2021, DST Global); Q4 2024 monthly profitable (90% COR) with 500K+ customers, 50 data points/sec telematics, cutting net loss £34M→£4M and 40% revenue growth 2025.
Zego is a London, United Kingdom-based commercial motor insurtech — having raised over $300 million total including a $150 million Series C led by DST Global in 2021 at a $1.1 billion valuation (the UK's first insurtech unicorn) — providing flexible, telematics-powered commercial motor insurance to over 500,000 UK drivers and businesses across five countries including delivery drivers, rideshare operators, and commercial fleets. Founded in 2016, Zego earned its own insurance license in 2019 — enabling it to build and underwrite its own policies, collecting 50 data points per second per vehicle (5x more than competitors) — rather than acting purely as a broker or MGA relying on capacity from traditional insurers. Zego has issued over 17 million policies covering 200,000+ vehicles with terms ranging from one hour to one year. In Q4 2024, Zego achieved monthly profitability with a 90% combined operating ratio, cutting its net loss from £34 million to £4 million in 2024. Revenue grew 40% in early 2025. CEO Sten Saar has led the company since founding.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.